Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qili Qiangxin Capsules for pulmonary hypertension due to left heart disease
ChiCTR2500100579Phase 4Not yet recruiting
- Sponsor
- Liaocheng City People's Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of qiliqiangxin in pulmonary hypertension due to left heart disease (PH-LHD), heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Liaocheng City People's Hospital. Primary endpoint: Pulmonary artery systolic pressure. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
qiliqiangxin
03
Conditions
pulmonary hypertension due to left heart disease (PH-LHD)heart failure with reduced ejection fraction (HFrEF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on ChiCTR2500100579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100579.